Biodesix, Inc. filings document the public reporting of a Nasdaq-listed diagnostics company with common stock trading under BDSX. The company’s 8-K reports disclose operating and financial results for its Diagnostic Testing and Development Services activities, including revenue trends, gross margin, guidance, and related press-release exhibits.
Proxy materials cover annual meeting proposals, board and governance matters, and stockholder voting. Other material-event filings document capital-structure and security-holder matters, including the completed one-for-twenty reverse stock split, common stock listing details, Nasdaq minimum bid price compliance, and amendments to the company’s charter.
Kieran O'Kane, Chief Commercial Officer of Biodesix, Inc. (BDSX), reported the vesting of restricted stock units and a small automatic sale to cover taxes. On 08/12/2025, 1,489 RSUs vested, each representing a contingent right to one share. Following vesting the filing shows 140,541 shares beneficially owned. On 08/13/2025, 476 shares were sold automatically to cover taxes at a weighted-average price of $0.4163, leaving the Reporting Person with 140,065 shares. The filing also reports 2,979 RSUs remaining outstanding that vest quarterly beginning February 8, 2022, subject to continued service, and these RSUs have no expiration date.
Biodesix, Inc. (BDSX) reporting person Gary Anthony Pestano, Chief Development Officer, had restricted stock units (RSUs) vest on 08/12/2025 that converted into 1,379 shares of common stock. The filing shows those 1,379 shares were recorded as acquired on 08/12/2025 and, to satisfy tax withholding, 442 shares were sold on 08/13/2025 at a weighted average price of $0.4163 per share (individual sale prices ranged from $0.4076 to $0.43). After these transactions, Mr. Pestano beneficially owned 157,878 shares of common stock. The RSUs vest quarterly in 16 installments beginning February 8, 2022, have no expiration date, and the sold shares were transacted automatically by the issuer's broker to cover taxes.
Chris Vazquez, Chief Accounting Officer of Biodesix, Inc. (BDSX), reported equity changes tied to vesting of restricted stock units (RSUs). On 08/12/2025 the reporting person was issued 602 RSUs, each representing a contingent right to one share of common stock; after vesting and automatic sales to cover taxes, the reporting person beneficially owned 18,603 shares. On 08/13/2025 the filing shows an automatic sale of 228 shares at a weighted average price of $0.4163 (sales occurred within a $0.4076–$0.43 range) resulting in 18,375 shares beneficially owned following the transactions. The RSUs vest in 16 successive quarterly installments beginning February 8, 2022, are generally conditioned on continued service, and have no expiration date.